[1]赵 添,邢亚明,于金平,等.生脉散联合阿托伐他汀对老年冠心病患者TLR4/MyD88/NF-κB信号通路的影响[J].陕西中医杂志,2021,(12):1703-1705,1720.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.012]
　ZHAO Tian,XING Yaming,YU Jinping,et al.Effect of Shengmai powder combined with Atorvastatin on TLR4/MyD88/NF-κB signaling pathway in elderly patients with coronary heart disease[J].,2021,(12):1703-1705,1720.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.012]
点击复制

生脉散联合阿托伐他汀对老年冠心病患者TLR4/MyD88/NF-κB信号通路的影响
分享到：

《陕西中医》杂志[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年12期
页码:
1703-1705,1720
栏目:
临床研究
出版日期:
2021-12-05

文章信息/Info

Title:
Effect of Shengmai powder combined with Atorvastatin on TLR4/MyD88/NF-κB signaling pathway in elderly patients with coronary heart disease
作者:
赵 添 1; 邢亚明2; 于金平 3; 赵 地2
(1.山东中医药大学第二附属医院,山东 济南 250001; 2.山东第一医科大学第三附属医院,山东 济南 250031; 3.山东省济南市章丘区中医医院,山东 济南 250200)
Author(s):
ZHAO Tian; XING Yaming; YU Jinping; ZHAO Di
(The Second Affiliated Hospital of Shandong University of Chinese Medicine,Jinan 250001,China)
关键词:
冠心病;  生脉散;  阿托伐他汀;  Toll样受体4;  髓样分化因子88;  核转录因子-κB
Keywords:
Coronary heart disease;  Shengmai powder;  Atorvastatin;  Toll-like receptor-4;  Myeloid differentiation factor 88;  Nuclear transcription factor kappa B
分类号:
R 541.4
DOI:
DOI:10.3969/j.issn.1000-7369.2020.12.012
文献标志码:
A
摘要:
目的:研究生脉散联合阿托伐他汀对老年冠心病(CHD)患者TLR4/MyD88/NF-κB信号通路的影响。方法:收集112例老年CHD患者作为研究对象,采用随机数字表法将患者分为观察组和对照组,每组56例。两组均接受常规治疗,对照组加用阿托伐他汀,观察组加用阿托伐他汀与生脉散。比较两组临床疗效、心功能指标[左室射血分数(LVEF)、左室舒张末内径(LVDD)及6 min步行距离(6MWD)],以及外周血TLR-4、MyD88、NF-κB mRNA和蛋白表达水平。结果:观察组总有效率高于对照组。治疗后,观察组TLR4、MyD88及NF-κB mRNA和蛋白表达低于对照组,差异有统计学意义(均P<0.05)。治疗后,观察组LVEF、6MWD水平高于对照组,差异有统计学意义(均P<0.05)。结论:生脉散联合阿托伐他汀治疗老年CHD疗效较好,可能与其调控TLR4/MyD88/NF-κB信号通路相关。
Abstract:
Objective:To study the effect of Shengmai powder combined with atorvastat in TLR4/MyD88/NF-κB signaling pathway in elderly patients with coronary heart disease(CHD).Methods:112 elderly patients with CHD were collected as research subjects,randomly divided into observation group and control group,56 cases in each group.The two groups received routine treatment.Atorvastatin was added in the control group,the atorvastatin and Shengmai powder were added in the observation group.The therapeutic effects,levels of cardiac function indexes [left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVDD)and 6 minutes walking distance(6MWD)],the TLR4,MyD88 and NF-κB mRNA and protein expression levels of the two groups were compared.Results:The total efficiency of the observation group was significantly higher than that of the control group.After treatment,the TLR4,MyD88 and NF-κB mRNA and protein expresstion in the observation group were significantly lower than those in the control group,difference statistically significant(all P<0.05).After treatment,the LVEF and 6MWD in the observation group were significantly higher than those in the control group(all P<0.05).Conclusion:Shengmai powder combined with atorvastatin is effective in the treatment of elderly CHD,which may be related to the regulation of TLR4/MyD88/NF-κB signaling pathway.

参考文献/References:

[1] 薛 强,曹雯丽,饶 莉,等.血管内超声评价他汀类药物治疗不稳定型心绞痛前后冠状动脉斑块稳定性的观察[J].临床心血管病杂志,2020,36(5):438-444.
[2] Rajathei DM,Parthasarathy SP,Selvaraj S,et al.Combined QSAR model and chemical similarity search for novel HMG-CoA reductase inhibitors for coronary heart disease[J].Curr Comput Aided Drug Des,2020,16(4):473-485.
[3] 段宝军,白 俊,何 莉,等.阿托伐他汀逆转BEL-7402/5-FU细胞多药耐药的体外实验研究[J].现代肿瘤医学,2017,25(21):3414-3419.
[4] 李 玲.加味生脉散联合西药治疗气阴两虚型冠心病合并高血脂疗效观察[J].陕西中医,2017,38(12):1643-1645.
[5] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694.
[6] 张军鹏,徐学功,徐变玲,等.基于数据挖掘方法的冠心病心绞痛合并糖尿病患者理化指标与气阴两虚证诊断模式的建立[J].中国中医基础医学杂志,2018,24(1):65-68,130.
[7] 中华医学会老年医学分会.老年患者6 min步行试验临床应用中国专家共识[J].中华老年医学杂志,2020,39(11):1241-1250.
[8] 黄 蓓.《证候类中药新药临床研究技术指导原则》发布[J].中医药管理杂志,2018,26(21):107.
[9] 中华中医药学会心血管病分会.冠心病心绞痛中医疗效评价标准[J].中国实验方剂学杂志,2018,24(15):7-10.
[10] 吴欣芳,吴 宝,王吉元,等. 升陷汤加味治疗冠心病室性早搏临床研究[J].陕西中医,2020,41(11):1563-1565.
[11] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.稳定性冠心病基层诊疗指南[J].中华全科医师杂志,2021,20(3):274-280.
[12] 董 昕,杨朋康.单硝酸异山梨酯联合维拉帕米对冠心病稳定型心绞痛患者血脂水平及血清同型半胱氨酸、高敏C反应蛋白的影响[J].陕西医学杂志,2020,49(4):485-488.
[13] 薛 磊,董 敏.阿托伐他汀钙片与心血管药物联用对冠心病患者的疗效及其对血管内皮功能及炎症因子的影响[J].抗感染药学,2019,16(4):667-669.
[14] 李玉竹,邹 梅,于 周.不同剂量阿托伐他汀对急性脑缺血/再灌注损伤大鼠血管内皮功能的影响及其与自噬相关信号通路Ca2+/AMPK/mTOR的关系研究[J].实用心脑肺血管病杂志,2019,27(5):50-56.
[15] 曹占鸿,潘建衡,李 娜,等.生脉散现代药理作用及作用机制的研究进展[J].中国实验方剂学杂志,2019,25(22):219-225.
[16] 刘顺民,王顺楷,徐顺霖.心脏康复运动训练持续时间对介入治疗后冠心病患者心肺功能、运动能力及内皮细胞功能的影响研究[J].实用心脑肺血管病杂志,2019,27(2):108-111.
[17] 冯六六,白艳艳,史 骏,等.血液循环中微小RNA-140-3p和Toll样受体4表达与冠心病患者经皮冠状动脉介入术后支架内再狭窄的关系研究[J].实用心脑肺血管病杂志,2020,28(12):21-26.
[18] 卫艳宁,徐晓辉,耿蓬勃,等.Toll样受体4在不同类型冠心病患者中的表达及与经皮冠状动脉介入术后支架内再狭窄的危险因素的相关性[J].中国心血管杂志,2019,24(5):419-423.
[19] 李红梅,王 显.TLR4/MyD88/NF-κB信号通路与动脉粥样硬化性心血管疾病的相关性研究进展[J].中国循证心血管医学杂志,2017,9(9):1132-1134.

相似文献/References:

[1]朱 薇.通脉调脂方治疗冠心病稳定性心绞痛疗效及对患者血流变、VCAM1〖JZ〗及ICAM1影响的研究*[J].陕西中医杂志,2019,(3):290.
　ZHU Wei..Effect of Tongmai Tiaozhi recipe on the efficacy, Hemorheology, VCAM1 and ICAM1 〖JZ〗in patients with stable angina pectoris of coronary heart disease[J].,2019,(12):290.
[2]时晓华.丹参多酚酸盐注射液辅助介入治疗冠心病 及对患者心、肾功能和心肌损伤的影响*[J].陕西中医杂志,2019,(5):568.
　SHI Xiaohua..Effects of salvianolate injection on cardiac function, renal function, myocardial injury in percutaneous coronary intervention postoperative patients with coronary heart disease[J].,2019,(12):568.
[3]刘 红,张玲燕,杨 玲.血府逐瘀汤治疗冠心病介入术后心绞痛临床研究[J].陕西中医杂志,2019,(5):594.
　LIU Hong,ZHANG Lingyan,YANG Ling..Clinical observation of Xuefu Zhuyu decoction in the treatment of angina pectoris after PCI for coronary heart disease[J].,2019,(12):594.
[4]吕永飞,陈爱莲.益心康泰胶囊治疗冠心病经皮冠状动脉介入术术后疗效及对患者血流变、血管内皮功能的影响*[J].陕西中医杂志,2019,(6):714.
　LV Yongfei,CHEN Ailian..Effect of Yixin Kangtai capsule on the curative effect hemorheology and vascular endothelial function after coronary artery disease PCI[J].,2019,(12):714.
[5]贺建涛,胡宇才,刘 磊.活血通络散治疗冠心病PCI术后心绞痛疗效研究*[J].陕西中医杂志,2019,(7):854.
　HE Jiantao,HU Yucai,LIU Lei..Efficacy observation of Huoxue Tongluo powder in the treatment of angina pectoris after coronary heart disease PCI[J].,2019,(12):854.
[6]解洪涛,张 顺△,曾广伟.当归补血方联合西药治疗冠脉搭桥术后疗效及对患者血瘀证证候评分和凝血功能的影响*[J].陕西中医杂志,2019,(10):1341.
　XIE Hongtao,ZHANG Shun,ZENG Guangwei..Effects of Danggui Buxue prescription combined with western medicine on blood stasis and coagulation function after coronary artery bypass grafting[J].,2019,(12):1341.
[7]索晓菲,王亚红△,王居新,等.软坚通脉汤治疗冠心病PCI术后Ⅱ期心脏康复疗效〖JZ〗及对患者生活质量的影响*[J].陕西中医杂志,2020,(1):29.
[8]尹 毅,李小兰△.益气活血汤联合尼可地尔治疗稳定性心绞痛疗效及对患者T淋巴细胞亚群的影响[J].陕西中医杂志,2020,(7):888.[doi:DOI:10.3969/j.issn.10007369.2020.07.014]
[9]季学清,刘 萍△,陈宝瑾,等.冠心康方加减联合西药治疗冠心病合并2型糖尿病气虚痰瘀证疗效研究*[J].陕西中医杂志,2020,(9):1208.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.008]
　JI Xueqing,LIU Ping,CHEN Baojin,et al.Efficacy of Guanxinkang preparation combined with western medicine in the treatment of coronary heart disease and type 2 diabetes mellitus with syndrome of Qixu Tanyu[J].,2020,(12):1208.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.008]
[10]董其浩,邓 兵.益脉强心汤对冠心病合并心衰患者心室重构及血清血小板活化因子、转化生长因子-β1的影响[J].陕西中医杂志,2021,(7):883.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.018]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81974561); 中国博士后基金资助面上项目(2020M672126); 山东省自然科学基金资助项目(ZR2019BH033)
更新日期/Last Update: 2021-12-09